Search
for
Sort by
Research 121–150 of 536
- Vitiligo—Current Treatment Options and Future Perspectives
- Alopecia Areata: An Updated Review for 2023
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
- Alopecia Areata: Current Treatments and New Directions
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Ritlecitinib in severe alopecia areata: a profile of its use
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
- 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making